← Leaderboards
Min Dong
Rhode Island Hospital
$364,055
Attributed
$549,063
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $323K · FY2022–23$500K$375K$250K$125K$0
'22
'23
Funding mix
By agency
NIH$549,063 · 2
By mechanism
R21$370,016 · 1
K01$179,047 · 1
Top collaborators
- Patrick Thomas Mcgann2 shared
Most similar at Rhode Island Hospital
Same institution · by research overlap
- Patrick Thomas McGann$3,173,320
Others in their field
Other Rising Stars on “Pharmacology”
- Lauren Miller · Technical Resources International, Inc.$31,120,905
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Mehrinfar Mahzad · Fisher Bioservices, Inc.$18,271,500
- Bambra Stokes · Ppd Development Lp$17,155,112
- Kevin V Grimes · Stanford University$14,783,804
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
Research focus
PharmacologySafetyFetal HemoglobinPharmaceutical PreparationsPhysiologicalResearch StudyDesignDrug KineticsHydroxyureaMortalityAffectClinical PharmacologyPhysiologyPreventAmericanClinical TrialsDoseDose IndividualizationFundingFutureAppropriate DoseChildChildhoodSickle Cell
Grant awards (4)
Developmental Pharmacology of Hydroxyurea Across the Age Span for the Treatment of Sickle Cell Anemia$174,023
R21 · FY2023 · HD
Model-Informed Evaluation of Hydroxyurea Exposure in Special Populations$52,023
K01 · FY2023 · MD · contact PI
Developmental Pharmacology of Hydroxyurea Across the Age Span for the Treatment of Sickle Cell Anemia$195,993
R21 · FY2022 · HD
Model-Informed Evaluation of Hydroxyurea Exposure in Special Populations$127,024
K01 · FY2022 · MD · contact PI